As of 2024-12-12, the EV/EBITDA ratio of Shield Therapeutics PLC (STX.L) is -1.00. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. STX.L's latest enterprise value is 32.65 mil GBP. STX.L's TTM EBITDA according to its financial statements is -32.70 mil GBP. Dividing these 2 quantities gives us the above STX.L EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 5.4x - 6.4x | 5.9x |
| Forward P/E multiples | 7.1x - 12.2x | 8.8x |
| Fair Price | (32.21) - (29.18) | (33.38) |
| Upside | -1271.4% - -1161.2% | -1313.9% |
| Date | EV/EBITDA |
| 2024-12-05 | -1.02 |
| 2024-12-04 | -1.02 |
| 2024-12-03 | -1.02 |
| 2024-12-02 | -1.02 |
| 2024-11-29 | -1.03 |
| 2024-11-28 | -1.02 |
| 2024-11-27 | -1.02 |
| 2024-11-26 | -1.03 |
| 2024-11-25 | -1.02 |
| 2024-11-22 | -1.02 |
| 2024-11-21 | -1.04 |
| 2024-11-20 | -0.98 |
| 2024-11-19 | -1.03 |
| 2024-11-18 | -0.98 |
| 2024-11-15 | -0.99 |
| 2024-11-14 | -0.99 |
| 2024-11-13 | -0.98 |
| 2024-11-12 | -0.98 |
| 2024-11-11 | -0.98 |
| 2024-11-08 | -1.00 |
| 2024-11-07 | -1.00 |
| 2024-11-06 | -1.00 |
| 2024-11-05 | -1.00 |
| 2024-11-04 | -1.01 |
| 2024-11-01 | -1.06 |
| 2024-10-31 | -1.06 |
| 2024-10-30 | -1.03 |
| 2024-10-29 | -1.16 |
| 2024-10-28 | -1.24 |
| 2024-10-25 | -1.29 |
| 2024-10-24 | -1.30 |
| 2024-10-23 | -1.30 |
| 2024-10-22 | -1.43 |
| 2024-10-21 | -1.43 |
| 2024-10-18 | -1.41 |
| 2024-10-17 | -1.43 |
| 2024-10-16 | -1.41 |
| 2024-10-15 | -1.45 |
| 2024-10-14 | -1.50 |
| 2024-10-11 | -1.45 |
| 2024-10-10 | -1.36 |
| 2024-10-09 | -1.31 |
| 2024-10-08 | -1.32 |
| 2024-10-07 | -1.31 |
| 2024-10-04 | -1.33 |
| 2024-10-03 | -1.39 |
| 2024-10-02 | -1.39 |
| 2024-10-01 | -1.38 |
| 2024-09-30 | -1.41 |
| 2024-09-27 | -1.47 |